Webinar Series – Session 2 (Rewriting Cancer's Code with Epigenetics)
Cancer is no longer viewed solely as a genetic disease. Emerging evidence highlights epigenetic reprogramming—dynamic and reversible modifications of DNA and histones—as a critical driver of tumor initiation, progression, and therapy resistance.
Join us for the second session of our webinar series, where we explore how epigenetics is reshaping modern oncology and opening new therapeutic opportunities.
Webinar Goals
• Understand key epigenetic mechanisms in cancer
• Explore FDA-approved epigenetic therapies
• Highlight innovative therapeutic strategies
• Discuss future directions and clinical applications
Key Takeaways
• Epigenetics as a hallmark of cancer
• Clinical success of epi-drugs
• Targeted epigenetic reprogramming
• Synergistic potential with chemo- and immunotherapy
• Emerging biomarker opportunities
Featured Speaker
Dr. Mohamed Elmasry, PhD
Lecturer of Genetics & Lead, Youth Science Club – Alexandria University
With over 12 years of experience in molecular genetics, Dr. Elmasry specializes in microbial genetics with a focus on epigenetic reprogramming in bacteria.
Who Should Attend
• Oncology researchers & clinicians
• Epigenetics and pharmacology scientists
• Pharma & biotech professionals
• Medical students and trainees
• Patients and science advocates
Don’t miss this insightful session exploring how epigenetic therapies are redefining cancer treatment.
Cancer is no longer viewed solely as a genetic disease. Emerging evidence highlights epigenetic reprogramming—dynamic and reversible modifications of DNA and histones—as a critical driver of tumor initiation, progression, and therapy resistance.
Join us for the second session of our webinar series, where we explore how epigenetics is reshaping modern oncology and opening new therapeutic opportunities.
Webinar Goals
• Understand key epigenetic mechanisms in cancer
• Explore FDA-approved epigenetic therapies
• Highlight innovative therapeutic strategies
• Discuss future directions and clinical applications
Key Takeaways
• Epigenetics as a hallmark of cancer
• Clinical success of epi-drugs
• Targeted epigenetic reprogramming
• Synergistic potential with chemo- and immunotherapy
• Emerging biomarker opportunities
Featured Speaker
Dr. Mohamed Elmasry, PhD
Lecturer of Genetics & Lead, Youth Science Club – Alexandria University
With over 12 years of experience in molecular genetics, Dr. Elmasry specializes in microbial genetics with a focus on epigenetic reprogramming in bacteria.
Who Should Attend
• Oncology researchers & clinicians
• Epigenetics and pharmacology scientists
• Pharma & biotech professionals
• Medical students and trainees
• Patients and science advocates
Don’t miss this insightful session exploring how epigenetic therapies are redefining cancer treatment.
